• 
  Dylan Moutachi, Janek Hyzewicz, Pauline Roy, Mégane Lemaitre, Damien Bachasson, et al.. Treadmill running and mechanical overloading improved the strength of the plantaris muscle in the dystrophin‐desmin double knockout (DKO) mouse. The Journal of Physiology, In press, ⟨10.1113/JP286425⟩. ⟨hal-04643936⟩
• 
  Amélie Vergnol, Alain Sureau, Eric Batsché, E. Lallemand, Massiré Traoré, et al.. CaVβ1A and CaVβ1E embryonic isoforms in adult skeletal muscle, a Mbnl1 related-expression. Myology 2024, Apr 2024, Paris, France. ⟨hal-04782481⟩
• 
  Medhi Hassani, Dylan Moutachi, Mégane Lemaitre, Alexis Boulinguiez, Denis Furling, et al.. Beneficial effects of resistance training on both mild and severe mouse dystrophic muscle function as a preclinical option for Duchenne muscular dystrophy. PLoS ONE, 2024, 19, ⟨10.1371/journal.pone.0295700⟩. ⟨hal-04501283⟩
• 
  Antonio Atalaia, Dagmar Wandrei, Nawel Lalout, Rachel Thompson, Adrian Tassoni, et al.. EURO-NMD registry: federated FAIR infrastructure, innovative technologies and concepts of a patient-centred registry for rare neuromuscular disorders. Orphanet Journal of Rare Diseases, 2024, 19 (1), pp.66. ⟨10.1186/s13023-024-03059-3⟩. ⟨hal-04460667⟩
• 
  Anita Kneppers, Sabrina Ben Larbi, Marine Theret, Audrey Saugues, Carole Dabadie, et al.. AMPKα2 is a skeletal muscle stem cell intrinsic regulator of myonuclear accretion. iScience, 2023, 26 (12), pp.108343. ⟨10.1016/j.isci.2023.108343⟩. ⟨hal-04729009⟩
• 
  Maggie Lutz, Miranda Levanti, Rebekah Karns, Genevieve Gourdon, Diana Lindquist, et al.. Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy. International Journal of Molecular Sciences, 2023, 24 (13), pp.10650. ⟨10.3390/ijms241310650⟩. ⟨hal-04259888⟩
• 
  Florent Porquet, Lin Weidong, Kévin Jehasse, Hélène Gazon, Maria Kondili, et al.. Specific DMPK-promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells. Molecular Therapy - Nucleic Acids, 2023, 32, pp.857 - 871. ⟨10.1016/j.omtn.2023.05.007⟩. ⟨hal-04287597⟩
• 
  Caroline Le Guiner, T Larcher, A Lafoux, G Toumaniantz, S Webb, et al.. Characterization of the muscular and cardiac diseases of the DMSXL mouse model, a transgenic mouse model for Myotonic Dystrophy type 1. American Society of Gene & Cell Therapy, May 2023, LOS ANGELES, United States. ⟨hal-04096181⟩
• 
  Ludovic Arandel. Développement d'une thérapie génique pour la Dystrophie Myotonique de type 1. Génétique humaine. Sorbonne Université, 2023. Français. ⟨NNT : 2023SORUS229⟩. ⟨tel-04238758⟩
• 
  Dylan Moutachi, Mégane Lemaitre, Clément Delacroix, Onnik Agbulut, Denis Furling, et al.. Valproic acid reduces muscle susceptibility to contraction‐induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy. Clinical and Experimental Pharmacology and Physiology, In press, ⟨10.1111/1440-1681.13804⟩. ⟨hal-04146953⟩

53 %